Literature DB >> 6335378

Cortical abnormalities in Alzheimer's disease.

N L Foster, T N Chase, L Mansi, R Brooks, P Fedio, N J Patronas, G Di Chiro.   

Abstract

Regional cerebral glucose metabolism, an index of neuronal activity, was compared in 20 patients with Alzheimer's disease and 8 age-matched normal volunteers by positron emission tomography following [18F]2-fluoro-2-deoxy-D-glucose administration. Overall cortical glucose utilization in the Alzheimer's group was 10 to 49% below that of control individuals. The posterior parietal cortex and contiguous portions of posterior temporal and anterior occipital lobes were most severely affected; frontal cortex was relatively spared. This pattern of cortical involvement is consistent with the major clinical features of Alzheimer's disease. Comparison of patients with early and more advanced dementia suggested that a substantial decline in glucose metabolism occurs before cognitive impairment becomes evident; once the patient is symptomatic, however, small additional metabolic decrements are associated with a marked deterioration in intellectual function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6335378     DOI: 10.1002/ana.410160605

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  50 in total

1.  Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles.

Authors:  U M Mann; E Mohr; M Gearing; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

2.  A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia.

Authors:  M O Habert; U Spampinato; J L Mas; M L Piketty; M C Bourdel; J de Recondo; P Rondot; S Askienazy
Journal:  Eur J Nucl Med       Date:  1991

3.  Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

Authors:  S Hoyer; K Oesterreich; O Wagner
Journal:  J Neurol       Date:  1988-01       Impact factor: 4.849

4.  A gandhian model of health: Looking at Alzheimer's disease.

Authors:  R C Weaver
Journal:  J Relig Health       Date:  1987-03

Review 5.  Molecular neuroimaging in Alzheimer's disease.

Authors:  William Jagust
Journal:  NeuroRx       Date:  2004-04

6.  Cerebral glucose metabolic abnormality in patients with congenital scoliosis.

Authors:  Weon Wook Park; Kuen Tak Suh; Jeung Il Kim; Ja Gyung Ku; Hong Seok Lee; Seong-Jang Kim; In-Ju Kim; Yong-Ki Kim; Jung Sub Lee
Journal:  Eur Spine J       Date:  2008-04-30       Impact factor: 3.134

Review 7.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 8.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  [Visual search in healthy persons and Alzheimer's patients: relating cognitive function to clinical practice].

Authors:  A Rösler; N Müller
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

10.  Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI).

Authors:  C Haense; K Herholz; W J Jagust; W D Heiss
Journal:  Dement Geriatr Cogn Disord       Date:  2009-09-25       Impact factor: 2.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.